Related Experiment Video
Updated: Jul 14, 2026
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
A rapid method for generating and characterizing anti-variable region monoclonal antibodies
Kimberly Staquet1, Deborah Kwok, Michael A Rycyzyn
1Centocor Research & Development Inc. 145 King of Prussia Rd., Radnor, PA 19087, USA. KStaquet@cntus.jnj.com
Human Antibodies
|May 25, 2007
Summary
Developing anti-variable region monoclonal antibodies (mAbs) is crucial for therapeutic antibody drug assessments. A new high-throughput ELISA method rapidly identifies optimal antibody pairs, saving time and resources in drug development.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Therapeutic antibody drug development requires robust pharmacokinetic/pharmacodynamic (PK/PD) assessments.
- Anti-variable region monoclonal antibodies (mAbs) are critical reagents for these PK/PD analyses, often necessitating specific non-competing antibody pairs.
- Generating large panels of anti-variable region mAbs efficiently is essential for increasing the success rate of identifying suitable reagents.
Purpose of the Study:
- To develop a rapid, high-throughput ELISA method for characterizing anti-variable region mAbs.
- To efficiently identify optimal anti-variable region antibody pairs from crude hybridoma supernatants.
- To streamline the process of generating and selecting reagents for therapeutic antibody PK/PD studies.
Main Methods:
- Utilized a previously described novel immunization method involving type 1 interferons (IFNs) and agonistic anti-CD40 mAb for rapid mAb generation.
- Developed and implemented an inexpensive, high-throughput ELISA assay for early-stage characterization of hybridoma supernatants.
- Focused on identifying specific, non-competing anti-variable region mAb pairs.
Main Results:
- Successfully developed a high-throughput ELISA method for rapid characterization of anti-variable region mAbs.
- Demonstrated the ability to efficiently identify optimal antibody pairs directly from crude hybridoma supernatants.
- The new method significantly reduces the time and labor associated with identifying suitable mAb reagents.
Conclusions:
- The developed high-throughput ELISA method accelerates the identification of critical anti-variable region mAb pairs for therapeutic antibody PK/PD assessments.
- This approach optimizes resource allocation by minimizing the need for extensive subcloning of irrelevant hybridomas.
- The method enhances the overall efficiency of generating essential reagents for drug development and clinical studies.
